Get a free quote

IV stem cell therapy.

An IV stem cell treatment is a drip of donor or your own cells into a vein, sold for anti-ageing, wellness and many conditions. Most of the cells are caught in the lungs, and the only FDA-approved use is a rare complication of bone marrow transplants.[1][2]

Get a free quoteCompare clinics

Written by Eli McGarvie.

Clinics that offer IV stem cell therapy.

Compare what they use it for and what they charge, then get a free quote.

All 11 clinics
ClinicUsed forAlso offersPrice from
Celltex MéxicoCancún, Mexico MSDiabetesArthritisALS Mesenchymal Not disclosed Longevity Medical InstituteSan José del Cabo, Mexico KneeShoulderHipBack pain MesenchymalExosomesInjections USD 1,425 Regeneris TherapyCancún, Mexico KneeBack painHair lossFace MesenchymalExosomesInjections Not disclosed Dream Body ClinicBucerías, Mexico KneeHipShoulderBack pain MesenchymalUmbilical cordInjections USD 1,750 Stem Cell InstitutePanama City, Panama AutismMSArthritisKnee Umbilical cordMesenchymal USD 15,890 AuragensPanama City, Panama KneeShoulderHipBack pain Umbilical cordMesenchymalExosomesInjections USD 14,500

IV stem cell therapy cost.

The lowest price clinics publish in each country.

Full cost guide
MexicoFromUSD 1,4254 clinicsPanamaFromUSD 5,0004 clinicsColombiaFromNot published1 clinicThailandFromNot published2 clinics

Where the cells go

Cells given into a vein are caught in the lungs on the first pass. In the one human tracking study, a third of the signal was in the lungs straight after the drip, moving to the spleen and liver over ten days.[1][3] In mice, living donor cells were found in the lungs for 24 hours and nowhere else.[4]

There is no human evidence that cells given by drip travel to the joint, brain or organ you want treated.[4]

Donor cells are mostly undetectable within 50 days. Researchers describe the effect as "hit and run".[5]

What to expect

The drip

An infusion of 30 to 90 minutes. Nobody in our review of patient accounts described it as painful, and clinics often add vitamins or an antihistamine to the line.[6] The approved product is given after a steroid and antihistamine to reduce reactions.[7]

How many drips

It depends on what is treated: one drip in kidney and frailty trials, eight over four weeks for the approved graft-versus-host treatment.[8][9][7] The usual dose in trials was 100 million cells, and in two frailty trials 200 million did worse than 100 million.[10][11][9]

Afterwards

Drowsiness within hours is the most common thing patients notice, and some describe a flu-like day or week.[6]

One FDA-approved use, and it is not anti-ageing

1intravenous stem cell product approved by the FDA: Ryoncil, for children with steroid-resistant graft-versus-host diseaseFDA approved products list[2][12]
About 208frail older adults across the three randomised trials of drips for ageing. None measured biological age, appearance or lifespan.Systematic review[13]
Noneof the trials supports adding a drip to a joint injectionReview comparing joint and drip delivery[14]
11 of 21patients who paid for a drip and reported online described a clear improvement, mostly in energy, sleep or pain. 7 saw no change.Our review of patient accounts on Reddit and forums[6]

Side effects

In trials, the one harm that stood out was fever, about two and a half times the control rate.[15] The risk specific to the drip is blood contact: the cells carry a clotting factor, and three members of one family had clots in the lungs after repeated fat-cell drips bought outside a trial.[16][17] About one in nine people given donor cells made antibodies against them, which can complicate a later transplant.[18]

Common questions

Can an infusion slow ageing?

No trial has tested it.[13]

Is it safer than an injection because it does not touch the joint?

No, it is a different set of risks: blood contact, infusion reactions and antibodies to the donor.[16][18]

Questions to ask a clinic

  1. What cells are in the drip, and how many?
  2. What else goes in the line, and why?
  3. How will cells in a vein reach the part of me you are treating?
  4. Can I see the certificate for my batch, including sterility?
  5. Has the product been tested for clotting risk?
  6. Who do I call if I get a fever or chest pain afterwards?

Sources

22 references
  1. Fischer UM, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells and Development, 2009. Link
  2. U.S. Food and Drug Administration. FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients. 2024. Link
  3. Gholamrezanezhad A, et al. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nuclear Medicine and Biology, 2011. Link
  4. Eggenhofer E, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Frontiers in Immunology, 2012. Link
  5. von Bahr L, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem cells (Dayton, Ohio), 2012. Link
  6. StemFinder review of first-hand patient accounts on Reddit and patient forums, 2026. Method
  7. U.S. Food and Drug Administration. RYONCIL (remestemcel-L-rknd) suspension for intravenous infusion: Highlights of Prescribing Information and Full Prescribing Information. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (BLA licence held by Mesoblast, Inc.), 2024. Link
  8. Perico N, et al. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). Journal of the American Society of Nephrology, 2023. Link
  9. Tompkins BA, et al. Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 2017. Link
  10. Kabat M, et al. Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range? Stem Cells Translational Medicine, 2020. Link
  11. Golpanian S, et al. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 2017. Link
  12. U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, 2026. Link
  13. Poutouri E, et al. Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review. International Journal of Molecular Sciences, 2026. Link
  14. Dias de Oliveira FB, et al. Comparative Effects of Intra-Articular versus Intravenous Mesenchymal Stromal Cells Therapy in a Rat Model of Osteoarthritis by Destabilization of Medial Meniscus. International Journal of Molecular Sciences, 2023. Link
  15. Thompson M, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine, 2020. Link
  16. Moll G, et al. Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products. Stem Cells Translational Medicine, 2022. Link
  17. Jung JW, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Medical Journal, 2013. Link
  18. Sanabria-de la Torre R, et al. Alloreactive Immune Response Associated to Human Mesenchymal Stromal Cells Treatment: A Systematic Review. Journal of Clinical Medicine, 2021. Link
  19. National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia. Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs) in Malaysia, Second Edition (September 2025). 2025. Link
  20. U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use; Guidance for Industry and Food and Drug Administration Staff (July 2020). U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, 2020. Link
  21. U.S. Food and Drug Administration. Warning Letter: Mother Stem Institute, Corp., 680118, 08/20/2024. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, 2024. Link
  22. Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). La COFEPRIS suspendió clínica del D.F. que ofrecía tratamientos con Células Madre sin aval científico. Gobierno de México, COFEPRIS (press release), 2015. Link

More treatments.

Stem cell therapy guide
Mesenchymal stem cellsExosomesUmbilical cord stem cellsStem cell injectionsPRP vs stem cells

Get a free quote
for IV stem cell therapy.

Tell us what you want treated and when you want to go. We put you in touch with the clinic you choose.

Get a free quote